Global Theranostics Market - 2025 -2033
Global Theranostics Market: Industry Outlook
The global theranostics market reached US$ 2.13 billion in 2023, with a rise to US$ 2.40 billion in 2024, and is expected to reach US$ 7.56 billion by 2033, growing at a CAGR of 15.4% during the forecast period 2025–2033. The theranostics market is experiencing robust growth, driven by the rising prevalence of cancer and other chronic diseases, the growing demand for personalized medicine, and advancements in molecular imaging and targeted therapies. Integration of diagnostics and therapeutics is enabling precise disease characterization, optimized treatment planning, and improved patient outcomes. Technological innovations, including novel radioisotopes, AI-powered imaging, and nanomedicine-based delivery systems, are further expanding clinical applications and accelerating adoption.
Key Market Trends & Insights
Driver: Rising Prevalence of Cancer and Chronic Diseases
The rising prevalence of cancer and chronic diseases is a major factor expected to drive the growth of the theranostics market. With cancer cases steadily increasing worldwide, there is a pressing need for more precise, targeted, and effective treatment options. Theranostics offers a unique advantage by combining diagnostic imaging and therapeutic intervention into a single platform, enabling accurate tumor detection, real-time monitoring, and tailored treatment strategies for individual patients. Beyond oncology, the growing burden of chronic conditions such as cardiovascular and neurological disorders further expands the potential applications of theranostics. As healthcare systems shift toward personalized and value-based care, the ability of theranostics to improve treatment efficacy, minimize side effects, and enhance patient outcomes positions it as a critical solution to address the rising global disease burden.
Restraint: High Cost of Theranostic Procedures
The high cost of theranostic procedures is anticipated to act as a significant restraint on the growth of the theranostics market. These treatments often involve advanced imaging technologies, specialized radiopharmaceuticals, and personalized therapeutic approaches, all of which substantially increase overall healthcare expenditure.
Global Theranostics Market Segment Analysis
The global theranostics market is segmented by imaging techniques, radioisotopes, application, and region.
Radioisotopes-The technetium-99 segment is estimated to have 47.6% of the theranostics market share.
The technetium-99 (Tc-99m) segment holds a dominant position in the theranostics market, primarily due to its widespread use in nuclear medicine for both diagnostic imaging and therapeutic applications. Tc-99m is favored for its optimal physical properties, including a short half-life that minimizes radiation exposure, and its ability to produce high-quality imaging results across a variety of conditions such as cancer, cardiovascular diseases, and neurological disorders.
Its versatility, cost-effectiveness, and compatibility with existing imaging infrastructure have made it the most commonly used radioisotope globally, accounting for the majority of diagnostic nuclear medicine procedures. Furthermore, the well-established supply chain, strong clinical validation, and ongoing research into expanding its applications continue to reinforce Tc-99m’s leadership in the theranostics market.
Geographical Analysis
The North America theranostics market was valued at 39.80% market share in 2024
North America is dominant in the theranostics market, accounting for the largest revenue share, supported by its advanced healthcare infrastructure, early adoption of precision medicine, and strong focus on oncology research. The region benefits from a high prevalence of cancer and chronic diseases, driving demand for innovative diagnostic and therapeutic solutions.
Well-established nuclear medicine facilities, widespread availability of advanced imaging technologies, and favorable reimbursement frameworks further enhance the adoption of theranostic approaches. In addition, significant investments from pharmaceutical companies, active collaborations between research institutions and healthcare providers, and a supportive regulatory environment continue to accelerate clinical trials and commercialization of novel theranostic agents. These factors collectively position North America as the leading market, with sustained growth expected throughout the forecast period.
The Asia-Pacific theranostics market was valued at 17.8% market share in 2024
Asia-Pacific is emerging as the fastest-growing region in the theranostics market, driven by a combination of rising cancer incidence, increasing adoption of personalized medicine, and expanding access to advanced healthcare technologies. Rapid urbanization and improved economic conditions have boosted healthcare spending, while governments across countries like China, India, South Korea, and Japan are actively investing in nuclear medicine infrastructure and research programs. Growing collaborations between local and global pharmaceutical companies, along with the establishment of specialized research hubs, are accelerating the development and availability of theranostic solutions in the region.
Competitive Landscape
The major players in the theranostics market include GE HealthCare, Siemens Medical Solutions USA, Inc., SDS Lifesciences Pvt. Ltd., NMR, among others.
Key Developments:
The global theranostics market reached US$ 2.13 billion in 2023, with a rise to US$ 2.40 billion in 2024, and is expected to reach US$ 7.56 billion by 2033, growing at a CAGR of 15.4% during the forecast period 2025–2033. The theranostics market is experiencing robust growth, driven by the rising prevalence of cancer and other chronic diseases, the growing demand for personalized medicine, and advancements in molecular imaging and targeted therapies. Integration of diagnostics and therapeutics is enabling precise disease characterization, optimized treatment planning, and improved patient outcomes. Technological innovations, including novel radioisotopes, AI-powered imaging, and nanomedicine-based delivery systems, are further expanding clinical applications and accelerating adoption.
Key Market Trends & Insights
- North America accounted for approximately 39.8% of the global theranostics market in 2024 and is expected to maintain its leading position throughout the forecast period. This dominance is supported by a strong presence of advanced healthcare infrastructure, high adoption of precision medicine, significant investment in oncology research, and the availability of cutting-edge diagnostic and therapeutic technologies.
- Asia-Pacific is projected to be the fastest-growing region, fueled by rising cancer prevalence, increasing demand for personalized treatment, expanding access to nuclear medicine facilities, and government initiatives supporting healthcare modernization in countries like China, India, and South Korea.
- 2024 Market Size: US$ 2.40 Billion
- 2033 Projected Market Size: US$ 7.56 Billion
- CAGR (2025–2033): 15.4%
- North America: Largest market in 2024
- Asia Pacific: Fastest-growing market
Driver: Rising Prevalence of Cancer and Chronic Diseases
The rising prevalence of cancer and chronic diseases is a major factor expected to drive the growth of the theranostics market. With cancer cases steadily increasing worldwide, there is a pressing need for more precise, targeted, and effective treatment options. Theranostics offers a unique advantage by combining diagnostic imaging and therapeutic intervention into a single platform, enabling accurate tumor detection, real-time monitoring, and tailored treatment strategies for individual patients. Beyond oncology, the growing burden of chronic conditions such as cardiovascular and neurological disorders further expands the potential applications of theranostics. As healthcare systems shift toward personalized and value-based care, the ability of theranostics to improve treatment efficacy, minimize side effects, and enhance patient outcomes positions it as a critical solution to address the rising global disease burden.
Restraint: High Cost of Theranostic Procedures
The high cost of theranostic procedures is anticipated to act as a significant restraint on the growth of the theranostics market. These treatments often involve advanced imaging technologies, specialized radiopharmaceuticals, and personalized therapeutic approaches, all of which substantially increase overall healthcare expenditure.
Global Theranostics Market Segment Analysis
The global theranostics market is segmented by imaging techniques, radioisotopes, application, and region.
Radioisotopes-The technetium-99 segment is estimated to have 47.6% of the theranostics market share.
The technetium-99 (Tc-99m) segment holds a dominant position in the theranostics market, primarily due to its widespread use in nuclear medicine for both diagnostic imaging and therapeutic applications. Tc-99m is favored for its optimal physical properties, including a short half-life that minimizes radiation exposure, and its ability to produce high-quality imaging results across a variety of conditions such as cancer, cardiovascular diseases, and neurological disorders.
Its versatility, cost-effectiveness, and compatibility with existing imaging infrastructure have made it the most commonly used radioisotope globally, accounting for the majority of diagnostic nuclear medicine procedures. Furthermore, the well-established supply chain, strong clinical validation, and ongoing research into expanding its applications continue to reinforce Tc-99m’s leadership in the theranostics market.
Geographical Analysis
The North America theranostics market was valued at 39.80% market share in 2024
North America is dominant in the theranostics market, accounting for the largest revenue share, supported by its advanced healthcare infrastructure, early adoption of precision medicine, and strong focus on oncology research. The region benefits from a high prevalence of cancer and chronic diseases, driving demand for innovative diagnostic and therapeutic solutions.
Well-established nuclear medicine facilities, widespread availability of advanced imaging technologies, and favorable reimbursement frameworks further enhance the adoption of theranostic approaches. In addition, significant investments from pharmaceutical companies, active collaborations between research institutions and healthcare providers, and a supportive regulatory environment continue to accelerate clinical trials and commercialization of novel theranostic agents. These factors collectively position North America as the leading market, with sustained growth expected throughout the forecast period.
The Asia-Pacific theranostics market was valued at 17.8% market share in 2024
Asia-Pacific is emerging as the fastest-growing region in the theranostics market, driven by a combination of rising cancer incidence, increasing adoption of personalized medicine, and expanding access to advanced healthcare technologies. Rapid urbanization and improved economic conditions have boosted healthcare spending, while governments across countries like China, India, South Korea, and Japan are actively investing in nuclear medicine infrastructure and research programs. Growing collaborations between local and global pharmaceutical companies, along with the establishment of specialized research hubs, are accelerating the development and availability of theranostic solutions in the region.
Competitive Landscape
The major players in the theranostics market include GE HealthCare, Siemens Medical Solutions USA, Inc., SDS Lifesciences Pvt. Ltd., NMR, among others.
Key Developments:
- In July 2025, Icon Cancer Centre and PMITC plan to open Western Australia’s first theranostics and molecular imaging facility at Hollywood Medical Centre, offering PET-CT, SPECT-CT, targeted radiopharmaceutical therapies, and access to global clinical trials.
- In June 2025, Siemens Healthineers Molecular Imaging entered a research collaboration with Massachusetts General Hospital (MGH) to advance the use of theranostics.
- In July 2025, Telix announced that its prostate cancer imaging agent, Illuccix (kit for the preparation of gallium-68 gozetotide injection), had received marketing authorization from BASG for detecting and localizing PSMA-positive lesions in adults with prostate cancer. This approval grants healthcare providers in Austria access to PSMA-PET imaging using a clinically validated gallium-based radiopharmaceutical, supporting broader clinical use in prostate cancer management.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Imaging Techniques
2.4. Snippet by Radioisotopes
2.5. Snippet by Application
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Cancer and Chronic Diseases
3.1.1.2. Advancements in Molecular Imaging and Radiopharmaceuticals
3.1.2. Restraints
3.1.2.1. High Cost of Theranostic Procedures
3.1.2.2. Short Half-life and Supply Challenges of Radioisotopes
3.1.3. Opportunity
3.1.3.1. Expansion into Emerging Markets
3.1.3.2. Integration of Artificial Intelligence and Big Data Analytics
3.1.4. Impact Analysis
4. GLOBAL THERANOSTICS MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established products & Services
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GLOBAL THERANOSTICS MARKET: BY IMAGING TECHNIQUES
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Techniques
5.1.2. Market Attractiveness Index, By Imaging Techniques
5.2. PET*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. SPECT
6. GLOBAL THERANOSTICS MARKET: BY RADIOISOTOPES
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotopes
6.1.2. Market Attractiveness Index, By Radioisotopes
6.2. Technetium-99*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Gallium-68
6.4. Lutetium (Lu) 177
6.5. Iodine-131
6.6. Zirconium-89
6.7. Y-90
6.8. Others
7. GLOBAL THERANOSTICS MARKET: BY APPLICATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Prostate Cancer*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Bone Metastasis
8. REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Techniques
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotopes
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Techniques
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotopes
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Techniques
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotopes
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Techniques
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotopes
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Techniques
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotopes
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. GE HealthCare*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.4.4. SWOT Analysis
10.2. Siemens Medical Solutions USA, Inc.
10.3. SDS Lifesciences Pvt. Ltd.
10.4. NMR (LIST NOT EXHAUSTIVE)
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.2.1.1.1. Forecasting Techniques
11.3. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Imaging Techniques
2.4. Snippet by Radioisotopes
2.5. Snippet by Application
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Cancer and Chronic Diseases
3.1.1.2. Advancements in Molecular Imaging and Radiopharmaceuticals
3.1.2. Restraints
3.1.2.1. High Cost of Theranostic Procedures
3.1.2.2. Short Half-life and Supply Challenges of Radioisotopes
3.1.3. Opportunity
3.1.3.1. Expansion into Emerging Markets
3.1.3.2. Integration of Artificial Intelligence and Big Data Analytics
3.1.4. Impact Analysis
4. GLOBAL THERANOSTICS MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established products & Services
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GLOBAL THERANOSTICS MARKET: BY IMAGING TECHNIQUES
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Techniques
5.1.2. Market Attractiveness Index, By Imaging Techniques
5.2. PET*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. SPECT
6. GLOBAL THERANOSTICS MARKET: BY RADIOISOTOPES
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotopes
6.1.2. Market Attractiveness Index, By Radioisotopes
6.2. Technetium-99*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Gallium-68
6.4. Lutetium (Lu) 177
6.5. Iodine-131
6.6. Zirconium-89
6.7. Y-90
6.8. Others
7. GLOBAL THERANOSTICS MARKET: BY APPLICATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Prostate Cancer*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Bone Metastasis
8. REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Techniques
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotopes
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Techniques
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotopes
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Techniques
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotopes
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Techniques
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotopes
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Techniques
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotopes
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. GE HealthCare*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.4.4. SWOT Analysis
10.2. Siemens Medical Solutions USA, Inc.
10.3. SDS Lifesciences Pvt. Ltd.
10.4. NMR (LIST NOT EXHAUSTIVE)
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.2.1.1.1. Forecasting Techniques
11.3. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
LIST OF TABLES
Table 1 Global Theranostics Market Value, By Imaging Techniques, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Theranostics Market Value, By Radioisotopes, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Theranostics Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Theranostics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Theranostics Market Value, By Imaging Techniques, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Theranostics Market Value, By Imaging Techniques, 2022-2033 (US$ Billion)
Table 7 Global Theranostics Market Value, By Radioisotopes, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Theranostics Market Value, By Radioisotopes, 2022-2033 (US$ Billion)
Table 9 Global Theranostics Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Theranostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 11 Global Theranostics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Theranostics Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Theranostics Market Value, By Imaging Techniques, 2022-2033 (US$ Billion)
Table 14 North America Theranostics Market Value, By Radioisotopes, 2022-2033 (US$ Billion)
Table 15 North America Theranostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 16 North America Theranostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Asia-Pacific Theranostics Market Value, By Imaging Techniques, 2022-2033 (US$ Billion)
Table 18 Asia-Pacific Theranostics Market Value, By Radioisotopes, 2022-2033 (US$ Billion)
Table 19 Asia-Pacific Theranostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 20 Asia-Pacific Theranostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Theranostics Market Value, By Imaging Techniques, 2022-2033 (US$ Billion)
Table 22 Europe Theranostics Market Value, By Radioisotopes, 2022-2033 (US$ Billion)
Table 23 Europe Theranostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 24 Europe Theranostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Theranostics Market Value, By Imaging Techniques, 2022-2033 (US$ Billion)
Table 26 South America Theranostics Market Value, By Radioisotopes, 2022-2033 (US$ Billion)
Table 27 South America Theranostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 28 South America Theranostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Theranostics Market Value, By Imaging Techniques, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Theranostics Market Value, By Radioisotopes, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Theranostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Theranostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 GE HealthCare: Overview
Table 34 GE HealthCare: Product Portfolio
Table 35 GE HealthCare: Key Developments
Table 36 Siemens Medical Solutions USA, Inc.: Overview
Table 37 Siemens Medical Solutions USA, Inc.: Product Portfolio
Table 38 Siemens Medical Solutions USA, Inc.: Key Developments
Table 39 SDS Lifesciences Pvt. Ltd.: Overview
Table 40 SDS Lifesciences Pvt. Ltd.: Product Portfolio
Table 41 SDS Lifesciences Pvt. Ltd.: Key Developments
Table 42 NMR: Overview
Table 43 NMR: Product Portfolio
Table 44 NMR: Key Developments
Table 1 Global Theranostics Market Value, By Imaging Techniques, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Theranostics Market Value, By Radioisotopes, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Theranostics Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Theranostics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Theranostics Market Value, By Imaging Techniques, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Theranostics Market Value, By Imaging Techniques, 2022-2033 (US$ Billion)
Table 7 Global Theranostics Market Value, By Radioisotopes, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Theranostics Market Value, By Radioisotopes, 2022-2033 (US$ Billion)
Table 9 Global Theranostics Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Theranostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 11 Global Theranostics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Theranostics Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Theranostics Market Value, By Imaging Techniques, 2022-2033 (US$ Billion)
Table 14 North America Theranostics Market Value, By Radioisotopes, 2022-2033 (US$ Billion)
Table 15 North America Theranostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 16 North America Theranostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Asia-Pacific Theranostics Market Value, By Imaging Techniques, 2022-2033 (US$ Billion)
Table 18 Asia-Pacific Theranostics Market Value, By Radioisotopes, 2022-2033 (US$ Billion)
Table 19 Asia-Pacific Theranostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 20 Asia-Pacific Theranostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Theranostics Market Value, By Imaging Techniques, 2022-2033 (US$ Billion)
Table 22 Europe Theranostics Market Value, By Radioisotopes, 2022-2033 (US$ Billion)
Table 23 Europe Theranostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 24 Europe Theranostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Theranostics Market Value, By Imaging Techniques, 2022-2033 (US$ Billion)
Table 26 South America Theranostics Market Value, By Radioisotopes, 2022-2033 (US$ Billion)
Table 27 South America Theranostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 28 South America Theranostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Theranostics Market Value, By Imaging Techniques, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Theranostics Market Value, By Radioisotopes, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Theranostics Market Value, By Application, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Theranostics Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 GE HealthCare: Overview
Table 34 GE HealthCare: Product Portfolio
Table 35 GE HealthCare: Key Developments
Table 36 Siemens Medical Solutions USA, Inc.: Overview
Table 37 Siemens Medical Solutions USA, Inc.: Product Portfolio
Table 38 Siemens Medical Solutions USA, Inc.: Key Developments
Table 39 SDS Lifesciences Pvt. Ltd.: Overview
Table 40 SDS Lifesciences Pvt. Ltd.: Product Portfolio
Table 41 SDS Lifesciences Pvt. Ltd.: Key Developments
Table 42 NMR: Overview
Table 43 NMR: Product Portfolio
Table 44 NMR: Key Developments
LIST OF FIGURES
Figure 1 Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Theranostics Market Share, By Imaging Techniques, 2024 & 2033 (%)
Figure 3 Global Theranostics Market Share, By Radioisotopes, 2024 & 2033 (%)
Figure 4 Global Theranostics Market Share, By Application, 2024 & 2033 (%)
Figure 5 Global Theranostics Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Theranostics Market Y-o-Y Growth, By Imaging Techniques, 2023-2033 (%)
Figure 7 PET Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 8 SPECT Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 9 Global Theranostics Market Y-o-Y Growth, By Radioisotopes, 2023-2033 (%)
Figure 10 Technetium-99 Radioisotopes in Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 11 Gallium-68 Radioisotopes in Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 12 Lutetium (Lu) 177 Radioisotopes in Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 13 Iodine-131 Radioisotopes in Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 14 Zirconium-89 Radioisotopes in Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 15 Y-90 Radioisotopes in Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 16 Others Radioisotopes in Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 17 Global Theranostics Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 18 Prostate Cancer Application in Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 19 Bone Metastasis Application in Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 20 Global Theranostics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 21 North America Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 22 North America Theranostics Market Share, By Imaging Techniques, 2024 & 2033 (%)
Figure 23 North America Theranostics Market Share, By Radioisotopes, 2024 & 2033 (%)
Figure 24 North America Theranostics Market Share, By Application, 2024 & 2033 (%)
Figure 25 North America Theranostics Market Share, By Country, 2024 & 2033 (%)
Figure 26 Asia-Pacific Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 27 Asia-Pacific Theranostics Market Share, By Imaging Techniques, 2024 & 2033 (%)
Figure 28 Asia-Pacific Theranostics Market Share, By Radioisotopes, 2024 & 2033 (%)
Figure 29 Asia-Pacific Theranostics Market Share, By Application, 2024 & 2033 (%)
Figure 30 Asia-Pacific Theranostics Market Share, By Country, 2024 & 2033 (%)
Figure 31 Europe Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 32 Europe Theranostics Market Share, By Imaging Techniques, 2024 & 2033 (%)
Figure 33 Europe Theranostics Market Share, By Radioisotopes, 2024 & 2033 (%)
Figure 34 Europe Theranostics Market Share, By Application, 2024 & 2033 (%)
Figure 35 Europe Theranostics Market Share, By Country, 2024 & 2033 (%)
Figure 36 South America Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 37 South America Theranostics Market Share, By Imaging Techniques, 2024 & 2033 (%)
Figure 38 South America Theranostics Market Share, By Radioisotopes, 2024 & 2033 (%)
Figure 39 South America Theranostics Market Share, By Application, 2024 & 2033 (%)
Figure 40 South America Theranostics Market Share, By Country, 2024 & 2033 (%)
Figure 41 Middle East and Africa Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 42 Middle East and Africa Theranostics Market Share, By Imaging Techniques, 2024 & 2033 (%)
Figure 43 Middle East and Africa Theranostics Market Share, By Radioisotopes, 2024 & 2033 (%)
Figure 44 Middle East and Africa Theranostics Market Share, By Application, 2024 & 2033 (%)
Figure 45 GE HealthCare: Financials
Figure 46 Siemens Medical Solutions USA, Inc.: Financials
Figure 47 SDS Lifesciences Pvt. Ltd.: Financials
Figure 48 NMR: Financials
Figure 1 Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Theranostics Market Share, By Imaging Techniques, 2024 & 2033 (%)
Figure 3 Global Theranostics Market Share, By Radioisotopes, 2024 & 2033 (%)
Figure 4 Global Theranostics Market Share, By Application, 2024 & 2033 (%)
Figure 5 Global Theranostics Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Theranostics Market Y-o-Y Growth, By Imaging Techniques, 2023-2033 (%)
Figure 7 PET Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 8 SPECT Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 9 Global Theranostics Market Y-o-Y Growth, By Radioisotopes, 2023-2033 (%)
Figure 10 Technetium-99 Radioisotopes in Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 11 Gallium-68 Radioisotopes in Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 12 Lutetium (Lu) 177 Radioisotopes in Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 13 Iodine-131 Radioisotopes in Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 14 Zirconium-89 Radioisotopes in Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 15 Y-90 Radioisotopes in Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 16 Others Radioisotopes in Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 17 Global Theranostics Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 18 Prostate Cancer Application in Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 19 Bone Metastasis Application in Global Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 20 Global Theranostics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 21 North America Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 22 North America Theranostics Market Share, By Imaging Techniques, 2024 & 2033 (%)
Figure 23 North America Theranostics Market Share, By Radioisotopes, 2024 & 2033 (%)
Figure 24 North America Theranostics Market Share, By Application, 2024 & 2033 (%)
Figure 25 North America Theranostics Market Share, By Country, 2024 & 2033 (%)
Figure 26 Asia-Pacific Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 27 Asia-Pacific Theranostics Market Share, By Imaging Techniques, 2024 & 2033 (%)
Figure 28 Asia-Pacific Theranostics Market Share, By Radioisotopes, 2024 & 2033 (%)
Figure 29 Asia-Pacific Theranostics Market Share, By Application, 2024 & 2033 (%)
Figure 30 Asia-Pacific Theranostics Market Share, By Country, 2024 & 2033 (%)
Figure 31 Europe Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 32 Europe Theranostics Market Share, By Imaging Techniques, 2024 & 2033 (%)
Figure 33 Europe Theranostics Market Share, By Radioisotopes, 2024 & 2033 (%)
Figure 34 Europe Theranostics Market Share, By Application, 2024 & 2033 (%)
Figure 35 Europe Theranostics Market Share, By Country, 2024 & 2033 (%)
Figure 36 South America Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 37 South America Theranostics Market Share, By Imaging Techniques, 2024 & 2033 (%)
Figure 38 South America Theranostics Market Share, By Radioisotopes, 2024 & 2033 (%)
Figure 39 South America Theranostics Market Share, By Application, 2024 & 2033 (%)
Figure 40 South America Theranostics Market Share, By Country, 2024 & 2033 (%)
Figure 41 Middle East and Africa Theranostics Market Value, 2022-2033 (US$ Billion)
Figure 42 Middle East and Africa Theranostics Market Share, By Imaging Techniques, 2024 & 2033 (%)
Figure 43 Middle East and Africa Theranostics Market Share, By Radioisotopes, 2024 & 2033 (%)
Figure 44 Middle East and Africa Theranostics Market Share, By Application, 2024 & 2033 (%)
Figure 45 GE HealthCare: Financials
Figure 46 Siemens Medical Solutions USA, Inc.: Financials
Figure 47 SDS Lifesciences Pvt. Ltd.: Financials
Figure 48 NMR: Financials
